[go: up one dir, main page]

MA35905B1 - Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens - Google Patents

Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens

Info

Publication number
MA35905B1
MA35905B1 MA37280A MA37280A MA35905B1 MA 35905 B1 MA35905 B1 MA 35905B1 MA 37280 A MA37280 A MA 37280A MA 37280 A MA37280 A MA 37280A MA 35905 B1 MA35905 B1 MA 35905B1
Authority
MA
Morocco
Prior art keywords
amidine
preparation
antibacterial agents
lactam compounds
substituted beta
Prior art date
Application number
MA37280A
Other languages
English (en)
Inventor
Burkhard Klenke
Irith Wiegand
Guido Schiffer
Heike Broetz-Oesterhelt
Samarendra N Maiti
Jehangir Khan
Andhe Reddy
Zhixiang Yang
Mostafa Hena
Guofeng Jia
Ou Ligong
Hong Liang
Judy Yip
Chuanjun Gao
Sabiha Tajammul
Rahim Mohammad
Ganguli Biswajeet
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA35905B1 publication Critical patent/MA35905B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne de nouveaux composés de
MA37280A 2012-01-24 2014-08-08 Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens MA35905B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (fr) 2012-01-24 2013-01-23 Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens

Publications (1)

Publication Number Publication Date
MA35905B1 true MA35905B1 (fr) 2014-12-01

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37280A MA35905B1 (fr) 2012-01-24 2014-08-08 Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens

Country Status (42)

Country Link
US (2) US9556165B2 (fr)
EP (1) EP2806873B1 (fr)
JP (1) JP5869701B2 (fr)
KR (1) KR102036393B1 (fr)
CN (1) CN104203237A (fr)
AP (1) AP2014007880A0 (fr)
AR (1) AR089796A1 (fr)
AU (1) AU2013211575B2 (fr)
BR (1) BR112014017968A8 (fr)
CA (1) CA2862338C (fr)
CL (1) CL2014001956A1 (fr)
CO (1) CO7101240A2 (fr)
CU (1) CU24273B1 (fr)
CY (1) CY1117955T1 (fr)
DK (1) DK2806873T3 (fr)
EA (1) EA027126B1 (fr)
EC (1) ECSP14010249A (fr)
ES (1) ES2592403T3 (fr)
HR (1) HRP20161171T1 (fr)
HU (1) HUE030452T2 (fr)
IL (1) IL233805A (fr)
IN (1) IN2014MN01640A (fr)
LT (1) LT2806873T (fr)
MA (1) MA35905B1 (fr)
ME (1) ME02532B (fr)
MX (1) MX346602B (fr)
MY (1) MY173843A (fr)
NZ (1) NZ626951A (fr)
PE (1) PE20142345A1 (fr)
PH (1) PH12014501671B1 (fr)
PL (1) PL2806873T3 (fr)
PT (1) PT2806873T (fr)
RS (1) RS55210B1 (fr)
SG (1) SG11201403930XA (fr)
SI (1) SI2806873T1 (fr)
SM (1) SMT201600354B (fr)
TN (1) TN2014000297A1 (fr)
TW (1) TWI659953B (fr)
UA (1) UA110880C2 (fr)
UY (1) UY34585A (fr)
WO (1) WO2013110643A1 (fr)
ZA (1) ZA201405057B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (fr) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactames et procédés de synthèse et d'utilisation de ces derniers
TWI714525B (zh) 2014-03-24 2021-01-01 瑞士商諾華公司 用於治療細菌感染之單內醯胺(monobactam)有機化合物
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
CN108137573B (zh) 2015-09-23 2021-06-11 诺华股份有限公司 单环内酰胺抗生素的盐和固体形式
EP3390357B1 (fr) 2015-12-15 2021-11-10 Merck Sharp & Dohme Corp. Composés de biarylmonobactame pour le traitement d'infections bactériennes
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
CN109863162B (zh) * 2016-08-26 2023-03-17 科德克希思公司 工程化亚胺还原酶和用于酮和胺化合物的还原胺化的方法
US20190365720A1 (en) 2016-11-18 2019-12-05 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
TW201828924A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 用於治療細菌感染之經脒取代之β-內醯胺化合物的脂質體調配物
CA3047634A1 (fr) 2016-12-21 2018-04-12 Aicuris Gmbh & Co. Kg Polytherapie avec des composes de ss-lactame substitues par amidine et des inhibiteurs de ss-lactamase pour des infections par des souches bacteriennes resistantes aux antibiotiques
JP2020527562A (ja) 2017-07-18 2020-09-10 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換3−ヘテロアリールオキシ−1h−ピラゾール類及びそれらの塩、並びに、それらの除草活性物質としての使用
UY37824A (es) 2017-07-28 2019-02-28 Aicuris Anti Infective Cures Gmbh Forma cristalina de ácido (2s)-2-[[(z)-[1-(2-amino-4-tiazolil)-2-[[(3s)-2,2-dimetil-4-oxo-1-(sulfoxi)-3-azetidinil]amino]-2-oxoetiliden]amino]oxi]-3-[4-[imino[(3r)-3-piperidinilamino]metil]fenoxi]-propanoico
EP3661933B1 (fr) 2017-08-02 2022-03-23 Novartis AG Procédé pour la préparation de 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)méthyl)-1-sulfoazétidin-3- yl)amino)éthylidene)amino)oxy)cyclopropane acide carboxylique
WO2019070492A1 (fr) * 2017-10-02 2019-04-11 Merck Sharp & Dohme Corp. Composés monobactames de chromane pour le traitement d'infections bactériennes
KR102455390B1 (ko) * 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
JP7280273B2 (ja) * 2018-01-29 2023-05-23 メッドシャイン ディスカバリー インコーポレイテッド 細菌感染を治療するための単環β-ラクタム化合物
US20220002288A1 (en) * 2018-11-13 2022-01-06 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
JP7179185B2 (ja) 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β-ラクタム化合物の使用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
EP4165039B1 (fr) * 2020-07-16 2024-08-21 Ningxia Academy of Agriculture and Forestry Sciences Nouveaux composés monobactam, leur préparation et leur utilisation en tant qu'agents antibactériens
CN114728953B (zh) * 2020-08-06 2024-04-09 宁夏农林科学院 β-内酰胺类化合物,及其制备方法以及其作为抗菌素的应用
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
GEAP202416514A (en) 2021-11-18 2024-08-26 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (fr) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (fr) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. Sulfate de [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoéthoxy]imino]acétyl]-amino]-2,2-diméthyl-4-oxo-1-azétidine
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (fr) 1989-09-21 1991-03-22 Peter H. Ermann Derives hydrazide heterocycliques de beta-lactam monocyclique antibiotique
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
PL218196B1 (pl) 2000-09-14 2014-10-31 Basilea Pharmaceutica Ag Izomery syn pochodnych kwasów 3-(heteroaryloacetamido) -2-oksoazetydyno-1-sulfonowych jako środki przeciwbakteryjne
CA2554333A1 (fr) 2004-01-27 2005-08-04 Merck Frosst Company Promedicaments liberant de l'oxyde nitrique de diaryl-2-(5h)-furanones utilises en tant qu'inhibiteurs de cyclooxygenase-2
CN101511187B (zh) 2005-09-23 2012-07-04 株式会社爱慕知科学 哌啶和哌嗪衍生物
EP2308874B1 (fr) 2005-12-07 2013-01-23 Basilea Pharmaceutica AG Monobactames pontés antibiotiques utiles comme inhibiteurs de bèta-lactamase
AR059375A1 (es) 2006-02-14 2008-03-26 Ihara Chemical Ind Co Procedimiento para produccion de 5-alcoxi-4-hidroximetilpirazol y compuestos
EP1994035A1 (fr) 2006-03-16 2008-11-26 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
JP2010521517A (ja) 2007-03-23 2010-06-24 バジリア ファルマスーチカ アーゲー 細菌感染症を処置するための組合せ薬
WO2009049028A1 (fr) 2007-10-09 2009-04-16 Targegen Inc. Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases
JP2012512863A (ja) * 2008-12-19 2012-06-07 ファイザー・インク モノカルバム

Also Published As

Publication number Publication date
US20150045340A1 (en) 2015-02-12
US20170100379A1 (en) 2017-04-13
CA2862338C (fr) 2019-04-16
HK1203389A1 (zh) 2015-10-30
BR112014017968A8 (pt) 2017-07-11
US9782390B2 (en) 2017-10-10
IL233805A0 (en) 2014-09-30
PH12014501671B1 (en) 2020-02-28
KR102036393B1 (ko) 2019-10-24
SG11201403930XA (en) 2014-08-28
EP2806873A1 (fr) 2014-12-03
RS55210B1 (sr) 2017-01-31
EA027126B1 (ru) 2017-06-30
NZ626951A (en) 2016-03-31
AU2013211575B2 (en) 2017-03-02
MX346602B (es) 2017-03-24
EA201400838A1 (ru) 2014-12-30
PL2806873T3 (pl) 2016-12-30
TN2014000297A1 (en) 2015-12-21
ME02532B (fr) 2017-02-20
WO2013110643A1 (fr) 2013-08-01
TW201343643A (zh) 2013-11-01
UA110880C2 (uk) 2016-02-25
PH12014501671A1 (en) 2014-11-10
CU24273B1 (es) 2017-08-08
JP2015504907A (ja) 2015-02-16
JP5869701B2 (ja) 2016-02-24
CN104203237A (zh) 2014-12-10
PT2806873T (pt) 2016-09-23
ZA201405057B (en) 2017-09-27
KR20140114390A (ko) 2014-09-26
HUE030452T2 (en) 2017-05-29
AP2014007880A0 (en) 2014-08-31
SI2806873T1 (sl) 2016-10-28
ECSP14010249A (es) 2015-12-31
BR112014017968A2 (fr) 2017-06-20
ES2592403T3 (es) 2016-11-30
CL2014001956A1 (es) 2014-11-07
LT2806873T (lt) 2016-10-10
IN2014MN01640A (fr) 2015-05-22
AU2013211575A1 (en) 2014-07-24
SMT201600354B (it) 2016-11-10
DK2806873T3 (en) 2016-08-29
CY1117955T1 (el) 2017-05-17
US9556165B2 (en) 2017-01-31
PE20142345A1 (es) 2015-01-09
CO7101240A2 (es) 2014-10-31
EP2806873B1 (fr) 2016-06-15
UY34585A (es) 2013-09-02
HRP20161171T1 (hr) 2016-11-04
IL233805A (en) 2016-06-30
AR089796A1 (es) 2014-09-17
MY173843A (en) 2020-02-24
CU20140090A7 (es) 2014-12-26
CA2862338A1 (fr) 2013-08-01
TWI659953B (zh) 2019-05-21
MX2014008915A (es) 2014-08-26

Similar Documents

Publication Publication Date Title
MA35905B1 (fr) Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens
JOP20180103A1 (ar) مركب صيدلاني
MA37940A2 (fr) Nouveaux dérivés bicycliques
EP2908824A4 (fr) Composés de dioxyde de thiadiazine substituée tricyclique utilisés en tant qu'inhibiteurs de bace, compositions et leur utilisation
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
GEP20166438B (en) Imidazopyrrolidinone compounds
EA201790781A3 (ru) Противовирусные соединения
EA201490037A1 (ru) Антагонисты trpv4
MX379300B (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201590854A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201291460A1 (ru) Олигобензамидные соединения и их применение
MA37618A1 (fr) Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
MA35877B1 (fr) Phénylimidazopyrazoles substitués et leur utilisation
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA20150280A2 (fr) Dérivés d'aryléthynyle
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
MA35943B1 (fr) Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{ [(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl) pyrimidin-2-yl]amino}
MA35938B1 (fr) Nouvelles combinaisons pour le traitement de la leucemie myeloide aigue ou de la leucemie myeloide chronique
MA35884B1 (fr) Agonistes mglu 2/3